Advertisement

Pathologic Assessment and Specimen Quality After Total Mesorectal Excision of Rectal Cancer

  • Hoguen KimEmail author
Chapter

Abstract

After introduction of total mesorectal excision in rectal cancer surgery and effective neoadjuvant therapy, a considerable improvement of clinical outcome had occurred in rectal cancer patients. The pathologic reports of resected rectal cancers provide valuable information for the adequacy of the surgical treatment and predictive factors for future therapy. The evaluation of completeness of resection, preparation of adequate specimen, and evaluation of prognostic and predictive factors through microscopic evaluation and molecular analysis should be included for the proper management of rectal cancer patients.

Keywords

Rectal cancer Total mesorectal excision Pathology report Circumferential resection margin Predictive factors 

References

  1. 1.
    Amin MB, et al; AJCC cancer staging manual. 8th edn. New York: Springer; 2016. 251–269.Google Scholar
  2. 2.
    Monson JR, et al. Practice parameters for the management of rectal cancer (revised). Dis Colon Rectum. 2013;56(5):535–50.CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Heald RJ, et al. The mesorectum in rectal cancer surgery–the clue to pelvic recurrence? Br J Surg. 1982;69(10):613–6.CrossRefPubMedPubMedCentralGoogle Scholar
  4. 4.
    Nagtegaal ID. Current concepts of colorectal cancer resection pathology. Histopathology. 2015;66(1):102–11.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Washington MK, et al. Protocol for the examination of specimens from patients with primary carcinoma of the colon and rectum. Arch Pathol Lab Med. 2009;133(10):1539–51.PubMedPubMedCentralGoogle Scholar
  6. 6.
    Bujko K, et al. Is the 1-cm rule of distal bowel resection margin in rectal cancer based on clinical evidence? A systematic review. Ann Surg Oncol. 2012;19(3):801–8.CrossRefGoogle Scholar
  7. 7.
    Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol Off J Am Soc Clin Oncol. 2008;26(2):303–12.CrossRefGoogle Scholar
  8. 8.
    Williams NS, et al. Reappraisal of the 5 cm rule of distal excision for carcinoma of the rectum: a study of distal intramural spread and of patients’ survival. Br J Surg. 1983;70(3):150–4.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Gosens MJ, et al. Circumferential margin involvement is the crucial prognostic factor after multimodality treatment in patients with locally advanced rectal carcinoma. Clin Cancer Res Off J Am Assoc Cancer Res. 2007;13(22 Pt. 1):6617–23.CrossRefGoogle Scholar
  10. 10.
    Perez RO, et al. Fragmented pattern of tumor regression and lateral intramural spread may influence margin appropriateness after TEM for rectal cancer following neoadjuvant CRT. J Surg Oncol. 2014;109(8):853–8.CrossRefPubMedGoogle Scholar
  11. 11.
    Vironen J, et al. Tumour regression grading in the evaluation of tumour response after different preoperative radiotherapy treatments for rectal carcinoma. Int J Color Dis. 2005;20(5):440–5.CrossRefGoogle Scholar
  12. 12.
    Park SY, et al. Is step section necessary for determination of complete pathological response in rectal cancer patients treated with preoperative chemoradiotherapy? Histopathology. 2011;59(4):650–9.CrossRefPubMedGoogle Scholar
  13. 13.
    Mandard A-M, et al. Pathologic assessment of tumor regression after perspective chemotherapy of esophageal carcinoma. Cancer. 1994;73(6):2680–6.CrossRefPubMedGoogle Scholar
  14. 14.
    Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Color Dis. 1997;12(1):19–23.CrossRefGoogle Scholar
  15. 15.
    Ryan R, et al. Pathological response following long-course neoadjuvant chemoradiotherapy for locally advanced rectal cancer. Histopathology. 2005;47(2):141–6.CrossRefPubMedGoogle Scholar
  16. 16.
    Bosman FT, World Health Organization, International Agency for Research on Cancer. WHO classification of tumours of the digestive system. Lyon: International Agency for Research on Cancer; 2010. p. 417.Google Scholar
  17. 17.
    Hugen N, et al. Colorectal signet-ring cell carcinoma: benefit from adjuvant chemotherapy but a poor prognostic factor. Int J Cancer. 2015;136(2):333–9.CrossRefPubMedGoogle Scholar
  18. 18.
    Karapetis CS, et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med. 2008;359:1757–65.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Cancer Genome Atlas Network. Comprehensive molecular characterization of human colon and rectal cancer. Nature. 2012;487:330–7.CrossRefGoogle Scholar
  20. 20.
    Woerner SN, et al. Microsatellite instability in the development of DNA mismatch repair deficient tumors. Cancer Biomark. 2006;2:69–86.CrossRefPubMedGoogle Scholar
  21. 21.
    Le DT, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372:2509–20.CrossRefPubMedPubMedCentralGoogle Scholar
  22. 22.
    Kim H, et al. Clinical and pathological characteristics of sporadic colorectal carcinomas with DNA replication errors in microsatellite sequences. Am J Pathol. 1994;145(1):148–56.PubMedPubMedCentralGoogle Scholar

Copyright information

© Springer Nature Singapore Pte Ltd. 2018

Authors and Affiliations

  1. 1.Department of PathologyYonsei University College of MedicineSeoulSouth Korea

Personalised recommendations